title: Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington's disease.
abstract: An abundance of research shows that magnetic resonance imaging (MRI) striatal volumes decrease long before diagnosis of Huntington's disease (HD) and closely track disease progression. Additional research indicates that these volumetric measures meet important criteria for a biomarker that can be used in clinical trials: They are 1) objectively measureable; 2) able to predict known endpoints; and 3) associated with known mechanisms of pathology of the disease. Researchers should consider formal application to regulatory agencies for biomarker status of volumetric MRI striatal measures, because these measures are anticipated to contribute significantly in the assessment of treatment effectiveness in HD.
authors.affiliation: Seattle Children's Research Institute, Seattle, Washington, USA.
authors.forename: Elizabeth H
authors.initials: EH
authors.lastname: Aylward
mesh_terms: D015415:Biomarkers / Q000378:metabolism*; D002986:Clinical Trials as Topic / Q000379:methods*; D003342:Corpus Striatum / Q000473:pathology*; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D008279:Magnetic Resonance Imaging
chemical_list: D015415:Biomarkers
keywords: Huntington's disease; MRI; biomarker; striatal volume